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Ca
2+-loaded calmodulin normally inhibits multiple Ca
2+-channels upon dangerous elevation of intracellular Ca
2+ and protects
cells from Ca
2+-cytotoxicity, so blocking of calmodulin should theoretically lead to uncontrolled elevation of intracellular Ca
2+.
Paradoxically, classical anti-psychotic, anti-calmodulin drugs were noted here to inhibit Ca
2+-uptake via the vanilloid inducible
Ca
2+-channel/inflamatory pain receptor 1 (TRPV1), which suggests that calmodulin inhibitors may block pore formation and
Ca
2+ entry. Functional assays on TRPV1 expressing cells support direct, dose-dependent inhibition of vanilloid-induced
45Ca
2+-
uptake at mM concentrations: calmidazolium (broad range)$trifluoperazine (narrow range).chlorpromazine/amitriptyline.-
fluphenazine..W-7 and W-13 (only partially). Most likely a short acidic domain at the pore loop of the channel orifice
functions as binding site either for Ca
2+ or anti-calmodulin drugs. Camstatin, a selective peptide blocker of calmodulin, inhibits
vanilloid-induced Ca
2+-uptake in intact TRPV1
+ cells, and suggests an extracellular site of inhibition. TRPV1
+, inflammatory
pain-conferring nociceptive neurons from sensory ganglia, were blocked by various anti-psychotic and anti-calmodulin drugs.
Among them, calmidazolium, the most effective calmodulin agonist, blocked Ca
2+-entry by a non-competitive kinetics,
affecting the TRPV1 at a different site than the vanilloid binding pocket. Data suggest that various calmodulin antagonists
dock to an extracellular site, not found in other Ca
2+-channels. Calmodulin antagonist-evoked inhibition of TRPV1 and NMDA
receptors/Ca
2+-channels was validated by microiontophoresis of calmidazolium to laminectomised rat monitored with
extracellular single unit recordings in vivo. These unexpected findings may explain empirically noted efficacy of clinical pain
adjuvant therapy that justify efforts to develop hits into painkillers, selective to sensory Ca
2+-channels but not affecting
motoneurons.
Citation: Ola ´hZ ,J o ´svay K, Pecze L, Letoha T, Babai N, et al (2007) Anti-calmodulins and Tricyclic Adjuvants in Pain Therapy Block the TRPV1
Channel. PLoS ONE 2(6): e545. doi:10.1371/journal.pone.0000545
INTRODUCTION
Recently, we and several other groups noted that TRPV1, the
vanilloid ligand gated member of the TRP (transient receptor
potential) super family, localizes both in the plasma membrane
(TRPV1PM) and endoplasmatic reticulum (TRPV1ER) membranes
[1–4], and upon ligand binding they release Ca
2+ to the cytosol.
These pools are inducible with: i) exo-, or endovanilloid ligands
[5,6], ii) proton [7,8], iii) phosphorylation via intracellular signaling
by protein kinases [9–11] and iv) heat (42–49uC) [12,13].
Dynamics of TRP cation channel opening and closing has
remained largely unknown, although various mechanisms have
been proposed [11,14]. Due to lack of purification and
crystallization protocol the three-dimensional (3D) structure
information is scarce, the initial conformation change and
subsequent steps leading to pore opening/closing has yet to be
elucidated. Better understanding of transmembrane proteins is
hampered by process development such as high scale production,
solubilization, and purification, which preserves the native state
and function. As in case of many transmembrane domain
proteins/ion channels, 3D structure of TRPV1 is still subject of
intense research [15,16].
Calmodulin is the most well-known calcium binding protein,
which is ubiquitous and preserved in the eukaryotic cell, either
human, animal, fungal or plant. Ca
2+, among others, selectively
interacts with the so-called ‘‘EF-hand’’/Ca
2+-binding protein
motifs located either intracellularly or extracellularly [17]. Dose-
dependent interaction of Ca
2+ with calmodulin elicits a robust
conformational change that exposes hidden hydrophobic domains
required for subsequent effects on down-stream protein targets
[18,19]. Ca
2+- calmodulin complex, formed upon entry of Ca
2+ to
the cytosol resulting in elevation of intracellular free calcium
[Ca
2+]i can turn on/off different enzymes and ion channels.
Camstatin, a recently found conserved polypeptide motif in PEP-
19, neurogranin and neuromodulin, has been noted to enhance
dissociation of Ca
2+ from calmodulin [20] and disable interaction
with down-stream targets [21]. These observations suggest that
one of the major functions of calmodulin would be to buffer and/
or neutralize the rapid increase of [Ca
2+]i, thus to prevent
excitotoxicity. Serving as a shut off valve on broad-spectra of Ca
2+-
channels, Ca
2+- calmodulin protects Ca
2+-overload-induced cell
death, either due to necrotic or apoptotic mechanisms. The
specific intracellular sites has been identified but the exact
mechanism of calmodulin binding is still debated [22,23].
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2+- calmodulin mediated feedback due to increased
[Ca
2+]i, has recently been elucidated in detail in case of the TRP3
channel. It has been noted that upon Ca
2+-depletion, IP3R,
a sensor of Ca
2+-load of ER, directly interacts and props the
TRP3PM channel open by the so-called ‘‘store operated Ca
2+-
entry’’ mechanism. Indeed, one or two specific domains of IP3R
can interact with cognate sites of TRP3PM and contribute to
opening of the pore. However, both Ca
2+- calmodulin and
cytoplasmic domain of IP3RER competes for an overlapping site
and either open or close the given TRP channel, respectively and
the preference only depends on the levels of [Ca
2+]i. In fact,
calmodulin, upon saturation with Ca
2+ displaces IP3RER, which
leads to termination of store operated Ca
2+ entry. However, Ca
2+-
calmodulin can be displaced by excess synthetic peptides, derived
either from the competitive IP3R motif or from the heterologous
myosin light chain kinase. The former is known to block IP3RER
binding to TRP3PM by direct competition, whereas, cognate
domain from myosin light chain kinase, as well as calmidazolium,
inhibit the interaction indirectly, due to prevention of Ca
2+ loading
of calmodulin. It is conceivable that either mechanism can serve as
a shut off valve of TRP3PM. In general, either disruption of a TRP-
Ca
2+-channel interaction or block of Ca
2+-feedback by anti-
calmodulin agents can deregulate store operated Ca
2+ entry and
cause eventually excitotoxicity and cell death by Ca
2+-overload
[24,25]. Indeed, application of calmidazolium to HL-60 cells has
recently been shown to increase [Ca
2+]i, which is consistent with
disrupted Ca
2+- calmodulin feedback regulation [26]. Ca
2+-
calmodulin-mediated termination of Ca
2+-entry is not confined to
TRP channels only [27], rise of [Ca
2+]i also shuts off M-, and L-type
voltage-gated channels. Opening of Ca
2+-activated, small conduc-
tance K
+ (SK) channels is elicited by calmodulin binding to the C-
terminus. Further elevation of [Ca
2+]i and saturation of calmodulin
with Ca
2+ inactivate the pore opening mechanism [28,29].
Consistent with this Ca
2+-feedback theory, anti- calmodulin
agents, such as calmidazolium are expected to suspend the
feedback on Ca
2+-entry, and thus potentiate elevation of [Ca
2+]i to
toxic levels [30]. Classical antipsychotic drugs, such as tri-
fluoperazine, chlorpromazine and fluphenazine also target cal-
modulin, so they were also hypothesised to deregulate agonist-
induced Ca
2+ increase. To test this hypothesis and better
understand channel function of TRPV1, we carried out experi-
ments with tricyclic anti-psychotic calmodulin antagonist drugs
and other selective inhibitors of calmodulin. Our new data, in lieu
of expectations, suggest that bona fide calmodulin antagonists blocks
and do not promote Ca
2+-transport via TRPV1.
To address paradoxical effects of anti- calmodulin agents, we
hypothesized that these compounds might not enter the cell, but
inhibit the pore opening of pain/TRPV1 channel, most likely
directly at the cation filter site, located at the extra-cellular orifice
of the Ca
2+-channel. In fact, sequence comparisons of various
TRP channels suggest that a short acidic amino acid stretch at the
pore loop of TRPV1 resembles to ‘‘EF-hand’’ and ‘‘Excalibur’’
motifs, both identified previously in calmodulin and calmodulin-
like proteins, respectively [31]. Since direct sequence homology
was not that obvious, structure and function of TRPV1 was
probed with various anti-calmodulin agents such as antipsychotic
drugs and homologues with basic pharmacophore similar to that
identified in calmidazolium. Functional assays were carried out in
TRPV1-NIH3T3 cells permanently expressing the receptor ectop-
ically, and in primary cultures from embryonic rat dorsal root
ganglia (DRG), enriched in TRPV1
+ nociceptor/pain neurons.
Consistent with our hypothesis, but contrary to the Ca
2+-
calmodulin feedback theory, a set of anti-calmodulin agents
acutely inhibited the vanilloid/capsaicin–induced Ca
2+-uptake in
TRPV1 expressing cells and neurons. Extracellularly added
camstatin peptide, an antagonist of calmodulin, also blocked
capsaicin–induced Ca
2+-uptake in intact cells. Studies carried out
at the cellular levels and in animal pain models were in concert
with previously noted analgesic actions of calmodulin-antagonists
determined in vivo [32], but we gave here new evidence that
calmodulin antagonists can directly block ion channel function of
TRPV1. We suggest that the analgesic effect of these calmodulin
antagonists is independent of conventional intracellular targets and
we propose a specific site of action located extracellularly [23].
Pharmacophores of various calmodulin inhibitors studied here
may yield discovery of novel analgesics in the near future [33].
RESULTS
To better understand potential effect of Ca
2+- calmodulin
inhibitors on nociception, activity of various phenothiazines were
studied at the molecular levels in TRPV1-NIH 3T3 cells, in which
the pain signal was mimicked with capsaicin-induced
45Ca
2+-
uptake (Fig. 1). Assays were carried out in 2610
25 M extracellular
Ca
2+ in 96 well plate formats at room temperature (22uC) for
10 min with robotic liquid handling. Briefly, cells were co-
incubated with capsaicin for vanilloid-induced opening of TRPV1.
Various Ca
2+- calmodulin inhibitors were co-incubated in pro-
gressively increasing concentration in the 2 mM capsaicin
supplemented incubation medium. Increased Ca
2+-uptake was
expected, due to a severe damage of shut off valve mechanism
caused by the presence of calmodulin antagonists. Contrary to this
theory, detailed referring to other TRP channels in the in-
troduction, we noted that the tested calmodulin inhibitors
inhibited the capsaicin-induced Ca
2+-uptake in TRPV1-NIH3T3
cells with varying potency: calmidazolium (IC50=7mM).trifluo-
perazine (IC50=9mM).chlorpromazine (IC50=70mM).W-7
(IC50,200 mM).fluphenazine (IC50,250 mM), and W-13
(IC50.300 mM), and [Ca
2+]i did not accumulate in these cells at
even higher concentrations of calmodulin inhibitors. The same
agents were also tested in the absence of capsaicin, where none of
them induced Ca
2+ influx, i.e., they did not activate the vanilloid
receptor. For the sake of clarity these curves were omitted from
Fig 1. and the following figures also (Fig 2–6). Efficacy of
calmidazolium in the mM scale was also validated in a human
TRPV1-HaCaT keratinocyte line (data not shown). Interestingly,
fluphenazine, but less pronouncedly both W13 and W7 increased
Ca
2+-uptake in the presence of 2 mM capsaicin at low concentra-
tions. Similar cooperative effect was noted previously between
[
3H] resiniferatoxin and different antipsychotic and antidepressant
drugs [34]. We hypothesized that calmodulin antagonists and
some registered drugs may exert their blocking effect with another
mechanisms on TRPV1 and not necessarily on their conventional
target. Acting extracellularly, the inhibitors prevent TRPV1
activation, therefore the intracellular calmodulin might be
secondary and has little if any effect on [Ca
2+]i signal induced
by inflammatory pain agonists either exo-, or endogenous.
To better define the quantitative structure-activity relationship
(qSAR), other miconazole compounds, analogs of the commer-
cially available calmidazolium, were functionally assayed in cells
expressing TRPV1. A small dedicated library of miconazoles,
clotrimazole and N-benzylimidazole compounds, referred to as the
M-set (see M1–M7 in Fig. 2) were tried. All of these analogues of
calmidazolium originally were synthesized to develop inhibitors of
L-type Ca
2+-channels [26]. Dose-response analysis of capsaicin-
induced Ca
2+-transport carried out in TRPV1-NIH 3T3 cells
eliminated N-benzylimidazole and clotrimazole compounds form
further studies, since both groups showed either only partial
inhibition or less favorable IC50 than calmidazolium and other
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2+-calmodulin inhibitors in TRPV1-NIH3T3 cells.
45Ca
2+-uptake experiments were carried out in 96 well plates
with robotic liquid handling. Cells were co-incubated with capsaicin (capsaicin, ED200=2mM) in the presence of different concentrations of Ca
2+-
calmodulin inhibitors. Calmidazolium (CMZ).trifluoperazine (TFP).chlorpromazine (CPZ) were identified as full antagonists of capsaicin-induced
Ca
2+-uptake, in the micromolar range, while fluphenazine (FluPhe), W7 and W13 were determined as partial or weak inhibitors. Similar efficacy order
was determined in two additional experiments, carried out in duplicate samples.
doi:10.1371/journal.pone.0000545.g001
Figure 2. Screening of other calmidazolium analogs (M-set). Among miconazoles, clotrimazole, and N-benzylimidazole compounds (M1–M7)
calmidazolium was the most potent inhibitor in TRPV1-NIH3T3 cells. Each point on the graph is the average of triplicate determinations. Chemical
structure of miconazoles, clotrimazole, and N-benzylimidazole compounds used in these studies are indicated. Experiments were repeated two
additional times in triplicate with similar results.
doi:10.1371/journal.pone.0000545.g002
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(Fig. 2).
Further kinetic analysis of calmidazolium addressed the
potential mechanism of inhibition in TRPV1 expressing cells. A
dramatic decrease in the maximal velocity (Vmax) of capsaicin-
induced Ca
2+-uptake, but not the ED50 of capsaicin (0.3 mM of
capsaicin) was determined. With progressively increasing concen-
trations of calmidazolium the Vmax gradually decreased, which
also showed a characteristic maxima instead of a plateau due to
a potential interaction with capsaicin on TRPV1. Above
a calmidazolium concentration of=2.5 mM, Ca
2+-transport was
almost completely abolished (Fig. 3a). Distinctive drop in Vmax
were prominent at low concentrations of calmidazolium, which is
rather consistent with a channel blocking mechanism, than
competition for the capsaicin-binding site. Likewise calmidazo-
lium, chlorpromazine showed distinctive, non-competitive in-
hibition kinetics of Vmax (Fig. 3b).
Capsazepine, a known competitive inhibitor at the intracellular
vanilloid binding site, typically shifts the dose-response curve right
(Fig. 3c), but at low concentrations does not affect Vmax, similar to
that determined previously by a non-penetrating ligand of TRPV1
[35]. Inhibition kinetics of calmidazolium and chlorpromazine
were markedly differed from that determined to capsazepine,
a bona-fide vanilloid mimetic antagonist. A decline in Vmax, relative
to a plateau might be a sign of allosteric interaction of calmida-
zolium and chlorpromazine with other domain(s) (Fig. 3a and 3b)
that may affect access of capsaicin to TRPV1.
From these experiments we hypothesized that maybe a calmod-
ulin-like motif of TRPV1 is recognized extracellularly, therefore,
a calmodulin antagonist with poor membrane permeability can
exert inhibition without entering the cell. To address extracellular
targeting of TRPV1, camstatin, a recently identified, selective anti-
calmodulin peptide was coincubated with capsaicin in the Ca
2+-
uptake medium. Likewise conventional calmodulin inhibitors,
camstatin inhibited capsaicin -induced Ca
2+-transport (IC50=
11 mM) within 10 min of the assay in TRPV1-NIH3T3 cells.
Prompt inhibition of inducible Ca
2+-uptake suggested a rapid
interaction with a potential extracellular docking site(s) of TRPV1
(Fig. 4). As a control, CAMKII kinase inhibitor peptide, similar in
size to camstatin but distinct in biological activity, did not block
capsaicin-induced Ca
2+-uptake (data not shown). Experiments
with peptides suggested that camstatin and other anti-calmodulin
agents indeed recognize an extracellular domain of TRPV1.
To make initial structure activity relationship studies of TRPV1
inhibitors more complete and check efficacy of a clinically tried
drugs, amitriptyline, a known antidepressant in human [36],
gabapentine, a recently commercialized painkiller drug, and
carbamazepine, an amitriptyline analog prescribed for patients
with chronic back pain were tried in capsaicin-induced Ca
2+-
uptake experiments. Among these substances amitriptyline, a struc-
ture analogue of phenothiazines, was determined the best inhibitor
(IC50,60 mM), however, its effect was significantly less prominent
than that of trifluoperazine (IC50,10 mM). Carbamazepine, with
shorter side chain than that in amitriptyline was completely
inactive in this assay, while gabapentine showed partial inhibition
(Fig. 5). SAR of these drugs highlights the role of the aliphatic
extension tethering the tricyclic ring of these types of analogs.
To test selectivity and efficacy in an in vivo target, calmidazo-
lium, the best channel blocker of capsaicin-induced Ca
2+-uptake in
TRPV1-NIH3T3 cell was tried in sensory neurons, expressing
TRPV1 endogenously. Primary cultures were prepared from
embryonic (E14) rat DRGs. Along with calmidazolium other
polycyclic compounds were included in the vanilloid-induced
45Ca
2+-transport assays. SB 290157, a selective, high affinity,
Figure 3. Kinetics of Ca
2+-transport inhibition by calmidazolium (CMZ), chlorpromazine (CPZ) and capsazepine (CAZ) in TRPV1-NIH3T3 cells,
induced by increasing concentrations of capsaicin. Increasing doses of calmidazolium decreased Vmax of Ca
2+-transport, however, affinity of TRPV1
to capsaicin remained constant, as indicated. Likewise, chlorpromazine showed distinctive, non-competitive inhibition kinetics, similar to that
determined to calmidazolium, consistent with a channel blocking mechanism on TRPV1. In contrast to calmidazolium and chlorpromazine,
capsazepine, a bona fide vanilloid antagonist shifted the capsaicin dose-response curves right, however, above 1 mM behaved as a mixed kinetics
inhibitor, also decreased Vmax. Experiments were repeated two additional times in duplicates with similar results.
doi:10.1371/journal.pone.0000545.g003
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37157, a cell-permeable benzodiazepine inhibitor of mitochondri-
al Na
+/Ca
2+ exchanger, and flunarizine, a piperazine derivative
blocker of T-type cardiac Ca
2+ channels were included in assays in
DRG cultures. All of them were far less potent than calmidazo-
lium. Moreover, calmidazolium inhibited capsaicin-induced Ca
2+-
uptake in sensory neuron cultures with a higher potency than that
was determined in TRPV1-NIH3T3 cells (i.e. 0.6 mM vs. ,2 mM,
respectively) (Fig. 1 and Fig. 6). Although CGP-37157 and
flunarizine were determined partially active, in a relative broad
concentration range, calmidazolium was determined far more
potent (,3 fold) inhibitor in DRG cultures enriched in nociceptive
neurons with TRPV1 immunoreactivity (data not shown) (Fig. 6).
To validate in vivo efficacy of calmidazolium, experiments were
carried out in a total of 22 nociceptive specific (NS) or wide
dynamic range (WDR) spinal dorsal horn neurons in 16 lightly
anesthetized rats. Effects of calmidazolium were studied on the
heat evoked responses of dorsal horn neurons using noxious
peripheral heat stimuli delivered in every 3 min in the cutaneous
receptive field of the hind paw. After establishing stable baseline
control responses, calmidazolium was iontophoresed (i.e. with 100
nA) from one of the barrels of the compound electrode. Heat-
evoked responses of dorsal horn neurons were significantly
reduced the responses to peripheral noxious heat to a mean of
34623% (p,0.01, n=6) of pre- calmidazolium baseline control
(Fig. 7). The calmidazolium evoked inhibition reached its
maximum within 10 to 15 min after ejection and lasted
throughout the entire recording periods (about 2 hrs) of the
experiment. The monitored cells had excitatory receptive fields
located on one of the hind paws. These cells usually had little
spontaneous activity, located between 100–600 mm from the
surface of the dorsal horn, as estimated by microdrive readings.
Pain signaling, evoked by noxious heat to cutaneous receptive field
of the paw were most likely transduced by TRPV1 expressing
nociceptive neurons but occurrence of other heat sensors, such as
TRPV2, the super heat receptor, could not be rule out. Likewise to
that determined previously in TRPV1-NIH3T3 cells, TRPV1-
HaCaT keratinocyte lines and primary culture of nociceptive
neurons, calmidazolium inhibited the ratemeter recorded signals
of radiation heat pain in the rat (Fig. 7). Iontophoretically ejected
calmidazolium to the site of recordings validated potent inhibitor
activity of a calmodulin antagonist in vivo, in the spinal dorsal horn
neurons that noted previously in TRPV1 expressing cells.
In another set of experiments, effects of calmidazolium were
investigated on the responses of dorsal horn neurons evoked by
NMDA and kainic acid agonists of different glutamate receptors,
well characterized transducers of pain signals, more centrally.
Neuronal firing responses to iontophoresed NMDA or kainic acid
were typically fast in onset and short in duration (Fig. 8). Ejection
currents for these excitatory agents were delivered alternately in
every 2 min and were selected to produce a maximal peak height
of 50–70 spikes/s which corresponded to 300–400 action
potentials per stimulation epoch. Iontophoretic application of
calmidazolium produced significant reduction in responses to both
NMDA and kainic acid. Maximal inhibition of NMDA- or kainic
acid -evoked responses were reached 15–20 min after calmidazo-
lium application and remained so during the rest of the 2 hour
Figure 5. Activity of other drugs, similar to chlorpromazine and
trifluoperazine, on TRPV1. Amitriptyline (AMI), carbamazepine and
gabapentine were tried in cell based capsaicin-induced Ca
2+-uptake
experiments. Among these substances amitriptyline, a tricyclic ana-
logue of phenothiazines, was the best inhibitor, however, carbamaze-
pine with shorter side chain than amitriptyline was determined inactive.
Gabapentine showed only partial inhibition on TRPV1. Similar results
were obtained in two additional experiments carried out in triplicate.
doi:10.1371/journal.pone.0000545.g005
Figure 4. Effect of a non-membrane permeable inhibitor of
calmodulin on TRPV1-mediated Ca
2+-transport. Camstatin, a recently
identified, selective, 25-mer polypeptide blocker of calmodulin, was
employed, which inhibited capsaicin-induced Ca
2+-uptake with com-
parable activity (IC50=20mM) determined previously to other, more
conventional antagonists, of calmodulin in TRPV1-NIH3T3 cells. Results
with camstatin suggests calmodulin-like structure at the extracellular
domains of TRPV1. Experiments were repeated two additional times in
triplicate with similar results.
doi:10.1371/journal.pone.0000545.g004
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reduced the initial pain signals to 13612% (p,0.01, n=16),
however, responses to kainic acid were moderate, inhibited the
pre- calmidazolium baseline control responses to 47620%
(p,0.01, n=16). There was a significant difference between the
decreases of responses to NMDA versus kainic acid in the presence
of calmidazolium (13612% versus 47620%, respectively,
p,0.05) (Fig. 9).
DISCUSSION
Of important finding of these studies is that classical phenothia-
zines/antipsychotic drugs, all of them calmodulin inhibitors, also
can serve as blocker of current via the Na
+/Ca
2+-channel of
TRPV1, the specific transducer of heat/vanilloid-induced in-
flammatory pain. Among these drugs amitriptyline (i.e. ElavilH/
TeperinH) has clinically been tried in adjuvant therapy, and noted
effective in post-herpetic neuralgia and painful diabetic neurop-
athy [37–39]. Although previously was validated in clinical pain,
amitriptyline (IC50=60mM) not ranked among the most potent
inhibitors of TRPV1 channel in our cell-based assay.
Migraine might be treated with rationally chosen calmodulin
antagonist drugs currently available. Novel drug candidates such
as calmidazolium analogs (M-set) may even more promising in this
respect. Even when a patient is not clinically depressed,
antipsychotic drugs and tricyclic antidepressants could be
administered to fight with various forms of neuropathic pain.
Posttraumatic sympathetic dystrophy, postmastectomy pain, post-
herpetic neuralgia, some forms of cancer pain, and other variants
of neuropathic pain syndromes maybe addressed with novel
adjuvant treatment protocols, planned on our cell-based TRPV1
assays, which may help to select among a number of empirically
employed drugs (30+) and rationalize adjuvants’ selection.
Additional lead optimization may be enhanced with in silico
screening of drugs available now (Figs. 10 and 11) or new drugs
can reach the clinic sooner. For better specificity, however, we
need to redirect drugs from the pleiotropic calmodulin target to
docking site at the pore loop of TRPV1 (Figs. 10 and 11).
According to our results obtained in our TRPV1-NIH3T3/
HaCaT and DRG cell-based functional assays, as well as, in
laminectomised rat models, among clinically used pain adjuvant
medications, either trifluoperazine (i.e. TerfluzineH) or chlorprom-
azine (i.e. ThorazineH) would be a better choice than amitripty-
line. Amitriptyline and fluphenazine showed almost an order of
magnitude less blocking efficacy among the registered drugs on
TRPV1. TerfluzineH would be an adjuvant of choice in therapeutic
protocols to potentiate either efficacy of opioids or NSAIDs,
although, some other factors, for example inadvertent side effects,
specificity to calmodulin and ADMETox characteristics can modify
optimal selection. Calmidazolium, a miconazole type calmodulin
antagonistwasrankedtothe1
stplace.Weshowedinlaminectomised
rat models that calmidazolium inhibits pain response to noxious
heat, moreover firing evoked by NMDA and kainic acid. In the
spinal dorsal horn calmidazolium inhibits other channels than the
heat and inflammatory pain channel and it is active on NMDA and
kainic acid receptors that usually prolong the duration of pain state.
Calmidazolium, a not yet registered drug candidate, has previously
been administered intrathecally in rat pain models and noted indeed
analgesic [32]. Although was effective on the intrathecal route, some
inadvertent action on locomotion hasalsobeen revealed.Forhuman
use, calmidazolium needs additional structural modifications, both
with computational drug discovery and medical chemistry means
[40].
Calmodulin kinase II (CaMKII) mediated intracellular signaling
has recently been recognized to contribute to inflammation, pain
and hyperalgesia [41] and activate TRPV1 in primary afferent
neurons at the levels of spinal cord [11]. Although chemically
Figure 6. Efficacy of Ca
2+- calmodulin inhibitors in rat primary DRG cultures. Neuron cultures derived from embryonic rat DRGs readily show
inducible (10 fold over base line) activation with vanilloids due to endogenous expression of TRPV1. As with the TRPV1-NIH 3T3 cells, calmidazolium
was determined the most effective inhibitor of capsaicin-induced Ca
2+-uptake. As controls of specificity, flunarizine, SB 290157, and CGP 37157
showed only partial blocking activity in DRG neurons. Similar results were obtained in two additional experiments carried out in triplicate.
doi:10.1371/journal.pone.0000545.g006
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calmodulin inhibit both phases of the formalin-induced abdominal
pain and heat-induced tail-flick latency [32]. These in vivo
observations also contradict to the Ca
2+- calmodulin feedback
theory of action of these agents. Animal studies, adjuvant therapy in
the clinical practice and studies in this paper suggest that
antipsychotic calmodulin antagonist drugs rather elicit analgesia
instead of hyperalgesia and block Ca
2+-entry in peripheral
nociceptive neurons. calmodulin inhibitors showed non-competitive
inhibitor kinetics with increasing dose of capsaicin. Our screening
technology employs vanilloid/capsaicin-induced Ca
2+-uptake assays
in TRPV1 expressing cell lines, in the first round, then hits are
further tested and validated in primary neuron cultures from rat
embryonic DRG, enriched in TRPV1
+ nociceptors.
A number of the Ca
2+-transport experiments were carried out in
‘‘nominally zero Ca
2+’’ buffer (2610
25 M extracellular Ca
2+
([Ca
2+]o) that reveals agonist-induced Ca
2+-curents originating
from either outside sources or the ER, then further amplified by
Ca
2+ induced Ca
2+ release mechanism, has recently noted to occur
in TRPV1 immunopositive nociceptor neurons. By Ca
2+ induced
Ca
2+ release both TRPV1PM and TRPV1ER pools are actively
involved in pain signaling [42,43]. Ca
2+ induced Ca
2+ release is
usually followed by a currently recognized mechanism, so called
store operated Ca
2+ entry, which replenish the ER store emptied
by different Ca
2+-channels, including the Ca
2+/vanilloid-induced
TRPV1ER. The usual function of store operated Ca
2+ entry is to
maintain Ca
2+-homeostasis, around 1 mM in the ER, and
[Ca
2+]i=10
27 M, both essential for pain signaling in primary
afferents sensory neurons. Coupling between Ca
2+ induced Ca
2+
release and store operated Ca
2+ entry is now a well accepted
hypothesis, therefore, [Ca
2+]o is an ideal test-bead for searching
specific inhibitors affecting either one or both the TRPV1PM and
TRPV1ER pools. Contrary to that noted with other TRP channels,
calmodulin antagonists do not eliminate Ca
2+-feedback. Even
more, an initial observation with the camstatin peptide prompted
us to hypothesise that antipsychotic inhibitors of calmodulin
eliminate vanilloid-induced Ca
2+-uptake due to binding to an
extracellular domain of TRPV1. Likewise, calmidazolium may
block noxious heat-, NMDA- and kainic acid -induced pain
signaling by a mechanism that does not need internalization of the
compound in laminectomised rat. Of importance, calmidazolium
has explicit positive charge, and electrostatic interactions may be
required for specific docking at the pore loop of TRPV1 (Figs. 10
and 11). Classical antipsychotic drugs, calmidazolium and
camstatin may interact with TRPV1 on folds common in these
Ca
2+-binding proteins (i.e., at the Ca
2+-filter/binding region).
By comparative homology search we identified a highly acidic
domain near to the orifice of the Na
+/Ca
2+ channel. The
646DLEFTENYD acidic tetrad of TRPV1 is unique and more
extended stretch than that occurs in other TRPs in the TRPV1
(Fig. 10a). This motif is similar to the EF-hand (DXDXDGXXDXXE)
and ‘‘Excalibur’’ (DXDXDXXXXE), both of them Ca
2+ binding
consensus domains, identified previously incalmodulinand bacterial
calmodulin-like proteins, respectively [31]. Indeed, this acidic tetrad
is targeted by other positively charged inhibitors such as the R4W2
peptide and ruthenium red. Both are well characterized inhibitors of
capsaicin-induced Ca
2+-current via TRPV1 channel. Our theory is
that a short segment of the pore loop may mimic some feature of
Ca
2+-binding proteins where anti-calmodulin drugs dock and inhibit
down-stream signaling (Fig. 10). Ruthenium red is widely used as
a channel blocker in electrophysiology of sensory neurons, but only
just recently has been mapped to bind at the acidic tetrad of TRPV1
(Fig. 10). Camstatin, a highly basic and lysine rich polypeptide may
recognize this calmodulin-like region and block the TRPV1 channel
without internalization. This particular domain of the pore loop may
also serve as a cation filter and anti-calmodulin compounds can bind
after Ca
2+ binds first to this TRPV1 structure (Fig. 10), thereby
preventing pore opening [44,45]. Moreover, point mutatation
studies established docking both ruthenium red and R4W2 to this
structure. Conceivably, the most efficacious TRPV1 blockers have
basic chemical character due to nitrogen heteroatoms in the
structure that fit to the exposed acidic tetrad (Figs. 10 and 11)
[45]. Experiments with the above mentioned mutants of Garcia-
Martinez et al. and replacement experiment with radiolabeled
R4W2 will provide the ultimate evidence for our claim based on the
current experimental results and in silico docking studies.
Calmodulin, due to interaction with Ca
2+, undergoes a robust
conformationalchangeandexposeshiddenhydrophobicdockingsite
for trifluoperazine and other conventional calmodulin antagonists
[18,19,46]. By analogy, calmodulin-like mouth of the TRPV1 pore
may react just like that described to other EF-hand structures [31]
such as the S-100 Ca
2+-binding proteins and ‘‘Excalibur’’. Likewise,
camstatin, an R/K-rich polypeptide may inhibit TRPV1 with
a mechanism similar to other calmodulin antagonists of basic nature.
The bulkiness of camstatin in fact has prompted us to hypothesize
extracellular targeting of TRPV1 by anti-calmodulin drugs.
Moreover, recently identified pore blockers from venom of a spider
has further supported our TRPV1 channel blocker theory [46].
From selectivity point of view, calmidazolium, trifluoperazine,
and W-7 have been determined inactive on intermediate Ca
2+-
activated K
+ channels (IKCa) of human erythrocytes, which
indicates that these compounds can distinguish among different
Figure 7. Heat-induced pain signal inhibition of the best Ca
2+-
calmodulin inhibitor in the rat. Ratemeter recordings showing the
inhibitory effects of calmidazolium (CMZ) on responses of a spinal
dorsal horn neuron to noxious heat delivered to its cutaneous receptive
field on the paw. Panel A: Heat-evoked responses evoked in every 3 min
during the control period.. Panel B: Effects of iontophoresed CMZ on
the heat-evoked responses. Similar results were obtained in five
additional experiments. A representative recording is shown.
doi:10.1371/journal.pone.0000545.g007
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dazolium and W-7 are considered selective and potent inhibitors
of calmodulin, yet they act extremely differently on the TRPV1
target, which is an important issue in future drug discovery. Both
calmidazolium and W-7 were noted analgesic intrathecally in both
phases of formalin tests in the rat [32]. Oral bioavailability of
calmidazolium and additional derivatives, however, has yet to be
evaluated in various pain models. Antipsychotic drugs selected on
empirical bases can be ranked for rational adjuvants selection in
various pain indications. Our data suggest that application of
neuroleptics in severe cancer pain may enhance and complement
efficacy of conventional painkillers by direct inhibition of TRPV1
Ca
2+-channel, an alternative target not used by opiates and
NSAIDs. Our data in this paper consistent with specific action of
calmidazolium and other anti-calmodulin analogues on a short
acidic domain of TRPV1, at the cation filter region not found in
other TRP channels and Ca
2+-binding polypeptides mimicking
this region [46]. Better characterization of the extracellular
calmodulin-like structure by molecular modeling and in silico
screening might be exploited to design new generations of
painkillers, thereby the novel but irreversible inflammatory pain
neuron ablation technology [42,48–50] can be supplemented with
reversible channel blocker drugs both acting via TRPV1.
MATERIALS AND METHODS
Agents and abbreviations:
CGP-37157, 7-Chloro - 5 - (2 - chlorophenyl) - 1,5 - dihydro - 4,1 –
benzothiazepin - 2(3H) - one; KA, Kainate, [2S-[2a,3b,4b-
(1Z,3E,5R)]]-2-Carboxy-4-(5-carboxy-1-methyl-1,3-hexadienyl)-3-
pyrrolidineacetic acid; M1, Miconazole 1; M2, Miconazole 2; M3,
Miconazole 3; M4, Clotrimazole 4, M5, Clotrimazole 5; M6,
Figure 8. Calmidazolium (CMZ) differentially bocks NMDA-, and kainic acid (KA)-induced pain-responses. NMDA and kainic acid were
iontophoresed, sequentially, 2 min apart using 285 nA and 230 nA, respectively, then calmidazolium was ejected as shown, which markedly
inhibited the initial pain signals at the levels of dorsal horn neurons. Note the differential effects of calmidazolium on NMDA responses versus kainic
acid responses. Panel A: Responses to NMDA and kainic acid iontophoresed alternately in every 2 min. Panel B: Effects of iontophoresed
calmidazolium on the responses to these excitatory amino acids during the control period. Panel B: Differential effects of calmidazolium on the
NMDA- versus the kainic acid-evoked responses. Similar results were obtained in fifteen additional experiments. A representative recording is shown.
doi:10.1371/journal.pone.0000545.g008
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Diphenylethoxy)acetyl]-L-arginine; W-7, N- 6 – aminohexyl – 5 –
chloro - 1 naphtalenesulfonamide; W-13, N - (4 - Aminobutyl) – 5
- chloro -2- naphthalenesulfonamide.
Cell lines expressing TRPV1 ectopically
TRPV1-NIH3T3 mouse fibroblast line, ectopically expressing the rat
TRPV1 was established previously. For validation of some data in
human cells, a permanent TRPV1-HaCaT keratinocyte line was
prepared by drug selection, similar to that described previously [1–4].
Primary cultures expressing TRPV1 endogenously
Primary DRG cultures were prepared from E16 embryonic rats as
described previously then plated in 15 cm Petri dishes for 4 h to
remove the most adherent fibroblasts. For Ca
2+-uptake studies
primary afferents neurons cultured in 96 well plates (3610
3 cells/
well), coated with poly-D lysine/collagen, which yielded both
axons and dendrites bearing neurons due to neuronal growth
factor supplementation in the culture medium [1–4]. The
dendrites are large processes branching from the cell body that
taper in diameter further from the cell body. The axons are
a constant diameter and project over long distances from the cell
body. Before the ion transport experiment, culture medium was
removed and cells were washed three times.
45Ca-uptake assays
were carried out in ‘‘nominally zero Ca
2+’’ (i.e. 2610
25 M
extracellular Ca
2+ ([Ca
2+]o) in 25 mM Tris-HCl buffered Hanks’
balanced salt solution (pH 7.5), supplemented with 10 mM CaCl2
and 0.8 mM MgCl2medium (HCM) [1–4].
Vanilloid-induced
45Ca-uptake
Vanilloid agonist inducible calcium transport was assayed in
adherent cell lines ectopically expressing the C-terminally e-tagged
rat TRPV1 (3610
4 cells/well) and primary cultures prepared from
embryonic DRG, seeded in poly-D lysine/collagen coated 96 well
plates. The ED100 for capsaicin-induction was determined to be
,1 mM in TRPV1-NIH3T3 cells at pH 7.5. Therefore antagonist-
screening assays were carried out with 2 mM capsaicin, an excess
amount of agonist, which fully activates TRPV1 either in DRG
neuronsorinpermanentcelllinesectopicallyexpressingthevanilloid
receptor, but does not cause Ca
2+-cytotoxicity during the 10 min
incubation period. To probe the TRPV1 specificity of capsaicin-
induced
45Ca
2+-uptake, experiments were carried out in the parental
NIH 3T3 and HACAT cell lines and yielded negative results (data
not shown). The previously established cell lines and standardized
DRG cultures were extensively characterized for functional cell-
based TRPV1 studies [1–4]. Immediately before the transport assay,
cells were adapted to room temperature (20uC) for 5 min in HCM.
45Ca
2+-uptake was performed for 10 min at 20uCi nH C Mu s i n g
0.1 mCi
45Ca
2+ as radioactive tracer in a 100 ml final volume. To
stop
45Ca
2+-uptake, cells were rapidly changed back into 0.2 ml
HCM, washed 4 additional times with 0.2 ml HCM, and then lysed
in 80 ml/well RIPA buffer (50 mM Tris-HCl, pH 7.5, 150 mM
NaCl, 1% Triton X-100, 0.5% deoxycholate, 0.1% SDS, 5 mM
EDTA) for 30 min [1–4]. Aliquots of the solubilized cell extracts
were mixed with 120 ml Microscint-40 and counted in a 96 wellplate
liquid scintillation counter (TopCount-NXT, Packard).
Anesthesia and surgery
Extracellular single-neuron recordings were made in chloral
hydrate-anesthetized (4 g/kg initial dose, i.p., with supplemental
doses as required) male Wistar rats weighing between 350–450 g.
The head of the animal was mounted in a stereotaxic frame. The
lumbar enlargement (L3–L5 segments) was exposed by a lami-
nectomy and the spinal cord was covered with a pool of warmed
mineral oil to prevent drying. Rectal temperature as well as the
temperature of the mineral oil were monitored with temperature
probes and kept at 37uC by a warm water-heated blanket beneath
the rat and an infrared heat lamp from above. The level of
anesthesia was maintained so that the rats showed no sign of
discomfort but the tail flick reflex could be evoked by application
of noxious heat (43–45uC) or mechanical stimulus (squeeze) to the
tail. Recordings were only commenced at least 1 h after surgery.
All animal experiments were performed in accordance with
institutional animal welfare guidelines.
Extracellular recordings and iontophoresis
Compound recording/iontophoresis electrodes were made of
a seven barreled array of thin wall borosilicate glass capillary
tubings (Kation Scientific, Minneapolis, MN) The recording barrel
contained a low impedance (1 MV)7 - mm carbon fiber and drugs
were delivered from the surrounding barrels. Single unit
extracellular recordings were made from selected dorsal horn
neurons characterized by their responses to both innocuous (brush,
pressure) and noxious (pinch, squeeze that was felt as painful by
the experimenter) stimuli applied to the excitatory receptive fields
of the hind paw. Mechanical stimuli of increasing strength were
delivered by a small brush and three serrated clamps with
a graduated force. The experimenter released clamps so that force
was standard for each mechanical stimulus delivered over a period
of 3 s, and about 1 min were allowed to pass between trials.
Neurons were characterized as low threshold (LT), nociceptive
specific (NS) or wide dynamic range (WDR) by their responses to
mechanical stimuli of increasing strength. Extracellular signals
from dorsal horn neurons were amplified and filtered (300 Hz to
8 KHz) using an ExAmp-20K equipment and preamplifier
(Kation Scientific). Neuronal activity was displayed on an
Figure 9. Summary of the effects of calmidazolium (CMZ) on the
responses to heat or to iontophoresed excitatory amino acids of spinal
dorsal horn neurons of nociceptive specific (NS) or wide dynamic range
(WDR) types. Note the decrease of the responses in the presence of
calmidazolium. Asterisks denote significant differences by ANOVA
(**p,0.05, ***p,0.01) as compared to their respective controls or the
significant difference between the decrease of NMDA- and kainic acid -
evoked responses in thepresenceofcalmidazolium. See details in the text.
doi:10.1371/journal.pone.0000545.g009
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a WD-2 window discriminator (Dagan, Minneapolis, MN). The
number of action potentials per second was counted by the
computer and the resulting peristimulus time histograms were
displayed. Iontophoretic drug delivery and collection of experi-
mental data were performed by a multifunction data acquisition
board (PCI-1200, National Instruments, Austin, TX) placed in
a computer and programmed in LabVIEW 7 (National Instru-
ments). Delivery of drugs by microiontophoresis was performed
using Union-36 constant current source units (Kation Scientific).
Drug barrels of the combined electrodes contained one of the
following freshly made solutions: 100 mM N-methyl-D-aspartate
Na (NMDA) in 100 mM NaCl (pH 8.0), 20 mM kainic acid in
100 mM NaCl (pH 8.0), 5 mM calmidazolium chloride in
100 mM NaCl (pH 7.2) was prepared using a 100 mM calmida-
zolium in ethanol stock solution. NMDA and kainic acid were
ejected with negative iontophoretic currents ranging from 10 to
100 nA for 5 s in every 2 min. calmidazolium was ejected with
positive currents at 100 nA for 120 s. Retaining currents of
opposite directions between 3–10 nA were used for all drugs.
Heat stimulation
Single unit extracellular recordings were made from selected
dorsal horn neurons responding to noxious heat delivered by
a projector lamp focused on the blackened surface of the hind paw.
Skin temperature was monitored using an infrared thermometer.
Temperature ramps were generated from a holding temperature
of 30uC to a peak of 50uC at a rate of about 2uC/s. The heat
stimulus was turned off when skin temperature reached 50uC.
Data analysis
Statistical evaluations were made using the total number of spikes
minus background activity evoked during each epochof excitation by
heat stimuli or iontophoretic application of an excitatory compound.
The background neuronal discharge was calculated by averaging
a 15 s period of ongoing activity preceding each epoch of excitation
and this value was subtracted from the total number of evoked spikes.
Differences in magnitude between different response epochs of
a single cell were confirmed by one-factor analysis of variance (with
Student-Newman-Keuls test for post-hoc analysis) by comparing the
total number of spikes per excitation period. To make data from
different experiments more comparable, analysis of pooled data was
done after normalizing the baseline stimulus-evoked response to
100%. Means6SD of a number (n)o fo b s e r v a t i o n sa r eg i v e n
throughout. APvalue of ,0.05 was considered significant in all cases.
Molecular modeling of TM5-pore loop-TM6 domain
of TRPV1 and docking calmidazolium and
chlorpromazine to the extracellular portion
The preliminary channel domain model was used in a fixed
protein flexible ligand docking protocol using simulated annealing
Figure 10. (a) Homologous portions of various TRP channels, near the border of the pore loop and the 6
th transmembrane domain were aligned
with a validated R4W2 peptide similar in biochemical character to ruthenium red. An acidic tetrad motif DXEXXEXXD which can bind the positively
charged peptides in human and rat TRPV1, is absent in TRPV2/VRL1 and TRPV3, (both close homologues of TRPV1) as well as in distantly related TRPs
and bKcsA, a bacterial cation channel. An acidic sequence, partially similar to the heat sensitive TRPs, is present in the cold responsive TRPM8/CMR1.
Distant TRPV homologues do not share the acidic tetrad motif either, such as g/mOTRPC4 and hOSM, nonselective cation channel orthologues from
Gallus gallus (chicken), mouse, and human, respectively that confer sensitivity to extracellular osmolarity, mTRP12, another osmotically activated TRP
channel from mouse; mGFRCC, mouse growth factor receptor coupled channel; hVOC, Homo sapiens Kv4.3 potassium channel; dSha12, a ‘‘shaker-
like’’ potassium channel from Drosophila melanogaster.( b) The TM5-pore loop-TM6 region of TRPV1 is analogous to the ‘‘inverted teepee’’, pore-
forming domain of bKcsA. Side-view of the TRPV1 tetramer channel depicts the hypothetical pore at the middle. Arrows point to the putative
ruthenium red/R4W2 binding site in each TRPV1 subunits of the tetramer. (c) To better represent the simulated quaternary structure of TRPV1, a view
perpendicular to the plasma membrane is generated with the homo-tetrameric TRPV1 domain fragments. The position of acidic domain is noted by
an arrow in a single subunit in this view of the model.
doi:10.1371/journal.pone.0000545.g010
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Chemical Computing Group. The homotetramer of the TM5-
pore loop-TM6 domain of TRPV1 was built using the Swiss-
PdbViewer molecular graphics and the SWISS-MODEL com-
parative homology modeling program package [51–53]. The
Q8NER1 sequence from TrEMBL [54] was used as a target
protein. Transmembrane prediction using the TMHMM 2.0
server [55] was carried out to delineate the transmembrane
segments. The predicted extracellular pore loop together with the
fifth and sixth transmembrane helices were extracted from the full
length protein sequence and aligned with the sequence of the
bacterial K
+ channel KcsA [56]. The X-ray crystal structure of the
M1-pore loop-M2 of the KcsA was used (PDB accession code
1K4C) as a template for homology modeling. Optimization of the
loop regions was carried out by applying extensive constraint
minimization using the GROMOS96 [57] force-field implemen-
ted in Swiss-PdbViewer. The homotetramer structures were built
manually using the non-crystallographic symmetry operators
derived from the template. The final depictions of the S5-pore
loop-S6 segment of TRPV1 model were produced using the VMD
program [58]. The possible interactions between the channel
region of the tetrameric TRPV1 receptor complex and the
inhibitors were calculated with the Sybyl molecular modeling
package (litSYBYL molecular modeling software, version 7.1,
Tripos Associates Inc., 1699 Hanley Rd, St. Louis, MO 63144-
2913.) using the general Tripos force field for the ligands
containing chemical bonds unusual in biological macromolecular
modeling. The structure of the receptor-ligand complex was
approximated by minimizing with the prepositioned ligand. The
backbone of the residues of the receptor complex outside the 20
angstrom boundary from the inhibitor molecule were constrained
in a fixed position allowing larger movement of the neighboring
amino acids only. The calmidazolium, holding an inherent
positive charge, was fixed by closely surrounding Asp and Glu
residues. No aromatic-aromatic interactions were observed in-
dicating the dominance of charged residues in the channel
blocking process.
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